| ●Editorial | Fukushima M | 214-5 |
| ●Public Debriefing Session 2010 Clinical trials of academia original seeds that began to move Organized by：Foundation for Biomedical Research and Innovation | 217-324 | |
| Annual Reports of Translational Research 2010 | Saruta T | 220 |
| Current status and networking of Translational Research Support Organizations | Nagai Y | 221-6 |
| Clinical trial of a novel artificial wrist joint (NM002) | Inage F，Iwasaki N，Minami A | 227-32 |
| Evaluation of efficacy and safety of a new hip arthroplasty implant (AMU001) for patients with functional disturbance of the hip joint | Hayashi H，Ito H，Tanino H，et al. | 233-7 |
| Investigation of safety and pharmacokinetics of N-acetylneuraminic acid in patients with Distal myopathy with rimmed vaculoles (DMRV) – hereditary inclusion body myopathy (hIBM) | Asada R，Aoki M | 238-43 |
| Clinical trial of novel bioabsorbable pericardial substitute | Kikuchi K，Tabayashi K，Saiki Y | 244-8 |
| The translational research of fetal electrocardiogram with non-connected wide range electrodes and the establishment of its clinical applications | Kikuchi K，Kimura Y，Satou N，Ito T | 249-54 |
| Trials in chronic skin ulcers using new collagen substitutes incorporating basic fibroblast growth factor (TR11) | Shimizu A，Suzuki S | 255-60 |
| Leptin-replacement therapy on lipodystrophy (TR06) | Shimizu A，Nakao K | 261-5 |
| Development of new strategy for severe heart failure using autologous myoblast sheets | Saito A，Miyagawa S，Yoshikawa Y，et al. | 266-71 |
| Cancer immunotherapy targeting Wilms’ tumor gene WT1 product | Ezaki H，Sugiyama H | 272-4 |
| An academia-sponsored Phase Ⅰ trial of BK-UM, a targeted-therapy drug candidate for ovarian cancer | Umegaki M，Miyamoto S，Mekata E | 275-80 |
| Clinical trial of the malaria vaccine for travellers | Okada K，Horii T，Ishii K，Tetsutani K | 281-6 |
| Intramuscular transplantation of autologous peripheral blood CD34＋ cells into patients with critical limb ischemia | Wada J，Kawamoto A | 287-9 |
| Regenerative therapy for osteoarthritis by cultured autologous chondrocytes | Go M，Kuroda R | 290-2 |
| Clinical trial of a novel RNA drug based on recombinant Sendai virus for
the treatment of peripheral arterial disease | Uchiyama M，Yonemitsu Y，Matsumoto T，et al. | 293-9 |
| The development of vascular endothelial cell selective nanotechnology based drug delivery system for less invasive nanotherapy | Nakano K，Egashira K | 300-4 |
| Development of a novel therapy for malignant mesothelioma by humanized anti-CD26 antibody | Morimoto C，Hosono O | 305-8 |
| Clinical development of oncolytic virus therapy | Todo T | 309-14 |
| Coordination, Support and Training Program for Translational Research – Another awareness gap regarding funding | Koga T | 315-6 |
| Summation and direction to the next step – Network management for innovation | Fukushima M | 317-22 |
| ●International symposium of early stage clinical trial in Beppu Why do we focus on early stage clinical trials now? Organized by：Clinical Pharmacology Center, Oita University Hospital The Head of the Executive Committee：Ohashi K | 325-84 | |
| Why do we focus on early stage clinical trials now? | Ohashi K | 327-30 |
| PET and microdose study for early clinical trials in Japan | Morimoto T | 331-5 |
| Biomarkers and surrogate endpoints in clinical trials | Watanabe H | 336-9 |
| Regulatory view point for a use of biomarkers in drug development | Uyama Y | 340-4 |
| Exploratory clinical trials in early drug development | Uemura N | 345-8 |
| How to manage to include Japan in global clinical studies | Kunitada S | 349-56 |
| Experience of early clinical trials in Oita University Hospital | Suzaki Y | 357-61 |
| Experience in a multi-center Phase Ⅰ study in Japanese patients | Uchida E | 362-6 |
| The current status and policy of early stage clinical trials in Korea | Shin SG | 367-75 |
| Japanese policy for innovative drug development | Miyata T | 376-81 |
| Plenary discussion | 382-4 | |
| ●Interview | ||
| The nursing scientist as a principal investigator (PI) of clinical trials on dementia –Interview with Associate Professor Ruth A. Mulnard – ・Full text version in English is here ! | Mulnard RA （Interview and trans. by Kurihara C，Saio T） | 385-94 |
| ●Articles | ||
| Current status in the regulation of research that involves human subjects in South Korea and China | Motojima M，Ichikawa I | 395-406 |
| Factors associated with the continued participation of physicians in the study extension; From the experience of the CASE-J Extension | Kobayashi J，Ueshima K，Oe Y，et al. | 407-12 |
| ●Forum | ||
| New strategies for drug development using the exploratory early clinical trials approach | Yano T | 413-9 |
| ●Instructions for authors [Japanese] & [English] | 421-9 | |
| ●Editor's note | Hirotsu C | 431 |